Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02326974). This is a study registration, not published results. Lead sponsor: Dana-Farber Cancer Institute. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 164 participants (ACTUAL). Conditions: HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer. Interventions: DRUG: T-DM1; DRUG: Pertuzumab; PROCEDURE: Excision of tumor/mastectomy. Primary outcome measures: Rate of Pathologic Complete Response (pCR) by HER2 Amplification Status Non-Heterogeneous , Evaluate upon completion of breast surgery, up to approximately 24 weeks from study enrollment.. Brief summary: This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab